Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1801 to 1815 of 8236 results

  1. Troriluzole for spinocerebellar ataxia [ID6456]

    Awaiting development Reference number: GID-TA11549 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tucatinib with trastuzumab emtansine for treating HER2-positive unresectable or advanced breast cancer after a taxane, trastuzumab or both together [TSID11781]

    Awaiting development Reference number: GID-TA11110 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Tocilizumab for treating systemic sclerosis [ID1396]

    Awaiting development Reference number: GID-TA10346 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Tiratricol for treating Allan–Herndon–Dudley syndrome [ID6217]

    Awaiting development Reference number: GID-TA11192 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Tislelizumab for untreated unresectable hepatocellular carcinoma [TSID10683]

    Awaiting development Reference number: GID-TA11053 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. STS101 for treating acute migraine [TSID11782]

    Awaiting development Reference number: GID-TA11147 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]

    Awaiting development Reference number: GID-TA11507 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Talazoparib with enzalutamide for untreated hormone-sensitive metastatic prostate cancer with a homologous recombination repair mutation [ID6460]

    Awaiting development Reference number: GID-TA11534 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Lenacapavir for treating multidrug resistant HIV-1 [ID6196]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  10. MT633 FreeO2 Automatic Oxygen Titration

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  11. MT656 Paige Prostate AI system for the detection of prostate cancer

    Topic prioritisation

    Diagnostics guidance
    Topic prioritisation

  12. MT660 CerebAir for monitoring continuous, real-time EEG

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  13. MT658 Quit Genius for Smoking Cessation

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  14. MT684 Smart Peak Flow for monitoring asthma

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation

  15. The Insides System chyme reinfusion system (MT682)

    Topic prioritisation

    Medical technologies guidance
    Topic prioritisation